Navigation Links
Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
Date:1/17/2008

ng market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2006. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Synvista Therapeutics to be Featured on Wallst.net
2. Synvista Therapeutics to Present at the BIO InvestorForum 2007
3. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
4. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
5. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
6. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
9. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
10. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
11. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... REDWOOD CITY , Kalifornien und HILDEN, ... QIAGEN Clinical Insight ... Interpretation von Genvarianten und die Erstellung dazugehöriger ... und ESHG     QIAGEN N.V. ... QIA) gab heute die Markteinführung von QIAGEN ...
(Date:5/26/2015)... China , May 26, 2015 Tianyin ... company that specializes in the patented biopharmaceutical, modernized traditional ... (API), announced that the Company,s Annual Meeting of Shareholders ... scheduled to be held at the Company,s office located ... conference call, at 9:00 AM (local time in ...
(Date:5/26/2015)... , May 26, 2015 Pharmaco-Kinesis Corporation (PKC) ... recently convened at Shutters on the Beach in ... development status of the Company,s innovative Metronomic Biofeedback Pump ... locally deliver chemotherapy over time to a target site ... capacity and biofeedback system in real-time.  ...
(Date:5/26/2015)... 2015 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... protocol for the company,s Phase IIb trial of ORMD-0801, ... Drug Administration (FDA). The submission was made under the ... The Phase IIb study of ORMD-0801 for type 2 ...
Breaking Biology Technology:QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3
... failed in its bid to lure a Georgia stem cell company ... stem cell kits for researchers, apparently has found the financial backing ... of the University of Georgia . , ,Dick Leazer, a ... will remain in Georgia, despite an incentive package offered by the ...
... end). The online retailing tango is in full swing with ... changes everything. , ,We've heard this for years, and ... changes (both good and bad) in the ways we disseminate ... and sell goods and services. For retailers and consumers, the ...
... - NimbleGen Systems scientist Thomas Albert ... innovative uses for microarray technology in DNA sequence analysis, ... for NimbleGen, will be the lead investigator on a ... federal government's $3.4 million Cancer Genome Atlas pilot project. ...
Cached Biology Technology:Georgia stem cell company likely to stay put 2Online retailing "tango" is adding some steps 2Online retailing "tango" is adding some steps 3Online retailing "tango" is adding some steps 4Online retailing "tango" is adding some steps 5Online retailing "tango" is adding some steps 6
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading ... ways to more fully engage with their communities around ... industry-leading, privacy protected and secure API.  ... enables the most accessible, affordable, and convenient vehicle to ... The API will allow ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... PASADENA, Calif.Our belief as to whether we will likely succeed ... or losingdirectly affects the levels of neural effort put forth ... new brain-imaging study by neuroscientists at the California Institute of ... Richard A. Andersen, the James G. Boswell Professor of Neuroscience ...
... ASHEVILLE, NC USDA Forest Service Southern Research ... foresters, landowners and others concerned about nonnative invasive plants ... "A Field Guide for the Identification of Invasive Plants ... of the very popular "Nonnative Invasive Plants of Southern ...
... A unique blob-like creature that lived in the ocean approximately ... model in research published today in the journal Biology ... primitive species on early Earth looked like and how they ... on Earth today. The scientists, from Imperial ...
Cached Biology News:Caltech: Gain and loss in optimistic versus pessimistic brains 2Caltech: Gain and loss in optimistic versus pessimistic brains 3Forest Service updates free guide to 'Invasive Plants in Southern Forests' 2Ancient blob-like creature of the deep revealed by scientists 2
Porcine TNF-alpha/TNFSF1A ELISpot Development Module...
Request Info...
Services include subcloning into an expression vector. Tagged protein will be expressed in small scale for testing yield and solubility and then in 1L culture for large scale affinity purification. E...
...
Biology Products: